MedDataX Logo

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

NCT ID: NCT07119775

Last Updated: 2025-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

NCT03692312

Congenital Myotonic Dystrophy
COMPLETED PHASE2/PHASE3

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

NCT02858908

Myotonic Dystrophy 1
COMPLETED PHASE2

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

NCT05004129

Congenital Myotonic Dystrophy
RECRUITING PHASE2/PHASE3

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

NCT04327973

Pompe Disease Infantile-Onset
AVAILABLE

Miglustat in Niemann-Pick Type C Disease

NCT00517153

Niemann-Pick Type C Disease
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Myotonic Dystrophy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tideglusib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AMO Pharma Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM

Role: CONTACT

[email protected]
+44 (0)1270 270010

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMO-02 Expanded Access

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217 COMPLETED PHASE1/PHASE2
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 COMPLETED PHASE1/PHASE2
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
NCT06769633 RECRUITING PHASE2
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
NCT00912925 COMPLETED PHASE3
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
NCT02061137 COMPLETED PHASE1/PHASE2
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613 RECRUITING PHASE2/PHASE3
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA
NCT00884949 COMPLETED PHASE1/PHASE2
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT02618512 TERMINATED PHASE1/PHASE2
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
NCT03520751 NOT_YET_RECRUITING PHASE1/PHASE2
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
NCT02350816 TERMINATED PHASE2
A Study of RG1662 in Individuals With Down Syndrome
NCT01436955 COMPLETED PHASE1
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 COMPLETED PHASE1/PHASE2
Orphan Drugs for Inherited Metabolic Diseases
NCT05818566 COMPLETED
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
NCT03570931 ACTIVE_NOT_RECRUITING PHASE2/PHASE3
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
NCT07220603 RECRUITING PHASE2
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
NCT03879655 TERMINATED PHASE2/PHASE3
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
NCT01609062 TERMINATED PHASE2
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
NCT04117711 COMPLETED PHASE1/PHASE2
BMN 110 US Expanded Access Program
NCT01858103 APPROVED_FOR_MARKETING
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
NCT01515956 COMPLETED PHASE2
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
NCT01275066 COMPLETED PHASE3
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
NCT00672022 COMPLETED PHASE3
A Study to Evaluate Camoteskimab in Participants With Still's Disease
NCT04752371 TERMINATED PHASE1
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
NCT03771898 ACTIVE_NOT_RECRUITING PHASE2
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease
NCT05174039 COMPLETED PHASE1/PHASE2